Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MeiraGTx Holdings plc before investing.

In this article, we go over a few key elements for understanding MeiraGTx Holdings plc’s stock price such as:

• MeiraGTx Holdings plc’s current stock price and volume
• Why MeiraGTx Holdings plc’s stock price changed recently
• Upgrades and downgrades for MGTX from analysts
• MGTX’s stock price momentum as measured by its relative strength

About MeiraGTx Holdings plc (MGTX)

Before we jump into MeiraGTx Holdings plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Want to learn more about MeiraGTx Holdings plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MeiraGTx Holdings plc.

MeiraGTx Holdings plc’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, MeiraGTx Holdings plc’s stock price was $8.300.

MeiraGTx Holdings plc is up 1.22% from its previous closing price of $8.200.

During the last market session, MeiraGTx Holdings plc’s stock traded between $8.040 and $8.340. Currently, there are approximately 80.95 million shares outstanding for MeiraGTx Holdings plc.

MeiraGTx Holdings plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MeiraGTx Holdings plc Stock Price History

MeiraGTx Holdings plc’s (MGTX) price is currently down 8.59% so far this month.

During the month of November, MeiraGTx Holdings plc’s stock price has reached a high of $9.730 and a low of $7.300.

Over the last year, MeiraGTx Holdings plc has hit prices as high as $9.730 and as low as $4.550. Year to date, MeiraGTx Holdings plc’s stock is up 36.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MeiraGTx Holdings plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there was 1 analyst who downgraded MeiraGTx Holdings plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate MeiraGTx Holdings plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MeiraGTx Holdings plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MeiraGTx Holdings plc (MGTX) by visiting AAII Stock Evaluator.

Relative Price Strength of MeiraGTx Holdings plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, MeiraGTx Holdings plc has a weighted four-quarter relative price strength of 5.82%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how MeiraGTx Holdings plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MeiraGTx Holdings plc Stock Price: Bottom Line

As of November 28, 2025, MeiraGTx Holdings plc’s stock price is $8.300, which is up 1.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MeiraGTx Holdings plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.